Vertex Pharmaceuticals VRTX FX Effect on Cash
FX Effect on Cash at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's fx effect on cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Vertex Pharmaceuticals's FX effect on cash?
- Vertex Pharmaceuticals (VRTX) reported FX effect on cash of -$40.3M in Q1 2026.
- How has Vertex Pharmaceuticals's FX effect on cash changed year-over-year?
- Vertex Pharmaceuticals's FX effect on cash decreased by 232.1% year-over-year, from $30.5M to -$40.3M.
- What is the long-term trend for Vertex Pharmaceuticals's FX effect on cash?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's FX effect on cash has grown at a 92.1% compound annual growth rate (CAGR), from -$13.4M to $95M.
- What does FX effect on cash mean?
- The impact of exchange rate changes on the value of cash and equivalents held in foreign currencies.